3 Drugs Stocks Driving The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 117 points (-0.7%) at 16,295 as of Monday, April 7, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 843 issues advancing vs. 2,136 declining with 146 unchanged.

The Drugs industry currently sits down 1.4% versus the S&P 500, which is down 0.8%. Top gainers within the industry include Questcor Pharmaceuticals ( QCOR), up 13.7%, Biogen Idec ( BIIB), up 0.8% and Eli Lilly and Company ( LLY), up 0.6%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 3.6%, Actavis ( ACT), down 2.8%, Allergan ( AGN), down 2.3%, Forest Laboratories ( FRX), down 2.0% and AstraZeneca ( AZN), down 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $2.65 (0.9%) to $287.99 on average volume. Thus far, 629,926 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $279.04-$292.29 after having opened the day at $280.32 as compared to the previous trading day's close of $285.34.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $29.2 billion and is part of the health care sector. Shares are up 3.7% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.42 (0.8%) to $50.31 on average volume. Thus far, 3.6 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.4 million shares. The stock has ranged in price between $49.77-$50.89 after having opened the day at $49.77 as compared to the previous trading day's close of $49.89.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $84.3 billion and is part of the health care sector. Shares are down 6.1% year-to-date as of the close of trading on Friday. Currently there are 10 analysts who rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Celgene Corporation ( CELG) is up $0.00 (0.0%) to $137.38 on average volume. Thus far, 2.7 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $135.50-$140.68 after having opened the day at $136.60 as compared to the previous trading day's close of $137.38.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. Celgene Corporation has a market cap of $58.3 billion and is part of the health care sector. Shares are down 18.7% year-to-date as of the close of trading on Friday. Currently there are 22 analysts who rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip

Skechers Slumps in Pre-Market After Soft Guidance Overshadows Solid Q1

Skechers Slumps in Pre-Market After Soft Guidance Overshadows Solid Q1

Ericsson Rockets After Solid Q1 Following Cevian Push to Accelerate Turnaround

Ericsson Rockets After Solid Q1 Following Cevian Push to Accelerate Turnaround

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?